{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-23-000419","form_type":"8-K","ticker":"ALDX","cik":"0001341235","company_name":"Aldeyra Therapeutics, Inc.","filed_at":"2023-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.547177+00:00","generated_at":"2026-06-18T06:41:38.089693+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Aldeyra posts FY2022 net loss $62.0M, cash $174.3M; two NDAs under FDA review with PDUFA dates June and Nov 2023","bullets":["Net loss $62.0M ($1.06/share) vs $57.8M ($1.07/share) in 2021; R&D $47.3M, G&A $15.4M.","Cash $174.3M at Dec 31, 2022; runway into H2 2024, covering launch preparations if approved.","FDA Priority Review for ADX-2191 (vitreoretinal lymphoma) with PDUFA June 21, 2023; no filing issues identified.","FDA accepted NDA for reproxalap (dry eye disease) with PDUFA Nov 23, 2023; no advisory committee planned.","Upcoming: Phase 3 INVIGORATE-2 allergic conjunctivitis, Phase 2 ADX-2191 RP, Phase 2 ADX-629 cough results expected H1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-23-000419","json":"https://secwatch.observer/filing/0001157523-23-000419.json","markdown":"https://secwatch.observer/filing/0001157523-23-000419.md","text":"https://secwatch.observer/filing/0001157523-23-000419.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1341235/000115752323000419/0001157523-23-000419-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1341235/000115752323000419/a53358602.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T06:41:38.089693+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}